Filed in archive
Diagnostics, Methodologies and Instrumentation
, Genomics, Proteomics and Bioinformatics
by ruth on August 19, 2005
"We are extremely pleased with the decisions of the US, Canadian and European Patent Offices", says Dr Koen Kas, Chief Executive Officer at Peakadilly. "We are now able to operate on the world's most important pharmaceutical markets offering a proprietary platform for the discovery of protein biomarkers. The patent protection is an important milestone which opens up new opportunities for the marketing of our services and for the out-licensing of our technologies to partner companies."
This protemics technology can analyse huge sets of proteins and posttranslational modified proteins in clinical samples like blood or sputum, and can be useful during clinical trials to distinguish responders from non-responders in a specific therapeutic regimen. A review article discussing how such technologies can help in cancer therapeutics have been published by Dr. Kas in the European Journal of Cancer Prevention (abstract only, full text available to subscribers).
Tags:
proteomics
biomarker
biotech
patents
discovery
biomarker+discovery
protein+biomarker
patents+protein
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/8500
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Peakadilly Receives Patents for Protein Biomarker Discovery Technologies:
|
Rating: 6.00 out of 2 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
